Phospholipids in the Phospholipids in the management of autism management of autism
and degenerative and degenerative neurological diseasesneurological diseases
Victor A Marcial-Vega,MDVictor A Marcial-Vega,[email protected]
Orlando,Florida, 2013Orlando,Florida, 2013
President’s Cancer Panel President’s Cancer Panel Report 2010Report 2010
Integrative Medicine Integrative Medicine CentersCenters
Cleveland ClinicCleveland Clinic Johns Hopkins HospitalJohns Hopkins Hospital UCLAUCLA George Washington UniversityGeorge Washington University MD Anderson Cancer CenterMD Anderson Cancer Center MSK Cancer CenterMSK Cancer Center Massage, Nutrition, Acupunture, Massage, Nutrition, Acupunture,
PsycotherapyPsycotherapy
Integrative MedicineIntegrative Medicine
Recognizes a crucial Recognizes a crucial environmental role of toxins in the environmental role of toxins in the etiology and/or worsening of most etiology and/or worsening of most diseasesdiseases
Ex. Carbon-Petroleum based Ex. Carbon-Petroleum based energy production, plastics, energy production, plastics, pesticides, heavy metals.pesticides, heavy metals.
Heavy MetalsHeavy Metals
Present in 100% of the populationPresent in 100% of the population Marker of other toxins present in Marker of other toxins present in
organismorganism Higgins, 2012- Parts per trillion of Higgins, 2012- Parts per trillion of
mercury significant (up to mercury significant (up to 1/1,000,000,000,000) significant in 1/1,000,000,000,000) significant in production of diseaseproduction of disease
24 hour urine collections24 hour urine collectionsPuerto Rico, 2008-2012Puerto Rico, 2008-2012Marcial-Vega, et al, 2013Marcial-Vega, et al, 2013
mmmmmmmmmm
Metals % from 51 patients
Range(ug/g creatinine)
Lead 100% 52/52 0.1 - 79.1
Mercury 65% 34/52 0.3 - 12.30
Aluminum 92% 48/52 0.8 - 77.4
Arsenic 100% 52/52 1 - 105
Cadmium 98% 51/52 0.05 - 16.09
Gadolinium 71% 37/52 0.005 - 93.5
Nickel 65% 34/52 0.2 - 15.39
Uranium 33% 17/52 0.008 - .2
Pre and Post EDTA Pre and Post EDTA CalciumCalcium
metals pre post
Lead 1.0 62.2
Mercury 0.55 2.87
Aluminum 0.131 77.4
Arsenic 6 17
Gadolinium 0.844 78
Nickel 0.91 0
Uranium 0 0.183
PROVOCATION WITH EDTAPROVOCATION WITH EDTA
Conventional medicine discourages Conventional medicine discourages provocation because of increased provocation because of increased toxicitytoxicity
They recommend diagnosis with They recommend diagnosis with bloodblood
We have found the oppositeWe have found the opposite It is both diagnostic and therapeutic It is both diagnostic and therapeutic
under strict nutritional conditions under strict nutritional conditions
IV Push with EDTA CalciumIV Push with EDTA Calcium
245 patients245 patients 2010-20132010-2013 Median Age 57Median Age 57 Dose range 300-3000 mgDose range 300-3000 mg Median 2.4 gramsMedian 2.4 grams
IV Push with EDTA CalciumIV Push with EDTA Calcium
5 minute infusion/once a week5 minute infusion/once a week Lowering of total cholesterol, LDL 85%Lowering of total cholesterol, LDL 85% Lowering of glucose levels 92%Lowering of glucose levels 92% Disappearance of joint pains 95%Disappearance of joint pains 95% More energy and sleeping better 100%More energy and sleeping better 100%
Marcial-Vega, 2013 Marcial-Vega, 2013
Retrospective Review Retrospective Review of a Rejuvenation of a Rejuvenation
Program in the Program in the Management of Management of
CancerCancer
Victor A. Marcial-Vega, MDVictor A. Marcial-Vega, MDwww.marcialvegamd.com
San Juan, Puerto RicoSan Juan, Puerto Rico
April 2013April 2013
Treatment ProtocolTreatment Protocol
Nutritional SupplementationNutritional Supplementation Intravenous Vitamin C (+ or Intravenous Vitamin C (+ or
- EDTA)- EDTA) Ozone/Hyperthermia Ozone/Hyperthermia
showersshowers
Intravenous Intravenous TherapyTherapy
Vitamin C 20 gramsVitamin C 20 grams Vitamins B1, B6(100 mg), Vitamins B1, B6(100 mg),
B12 (1000ug)B12 (1000ug) Sterile water(250 cc)Sterile water(250 cc) EDTA 2-6 cc(3g/21ccEDTA 2-6 cc(3g/21cc))
Intravenous Intravenous TherapyTherapy
Three times a weekThree times a week 20 gram weekly increases 20 gram weekly increases
until 70 grams or tolerance until 70 grams or tolerance is reachedis reached
Dose range 50-70 gramsDose range 50-70 grams
Ozone/Ozone/Hyperthermia Hyperthermia
ShowersShowers5 days a week5 days a week1/2 hour treatments1/2 hour treatments98-103 degrees 98-103 degrees FahrenheitFahrenheit
ResultsResultsAge Range 8-80 years Age Range 8-80 years Median 56 yearsMedian 56 years
Median Follow-up 18 Median Follow-up 18 monthsmonths
Analysis on 40 patientsAnalysis on 40 patients
Initial ResponseInitial Response More than 50% More than 50%
reduction of reduction of tumortumor
Within 3 weeksWithin 3 weeks (A) 25/33= 76%(A) 25/33= 76% (B) 3/5 = 60%(B) 3/5 = 60% (C) 1/2 = 50%(C) 1/2 = 50% Overall = 72%Overall = 72%
18 months results18 months results No tumor after No tumor after
multiple multiple recurrences 2/33recurrences 2/33
Complete Complete Response 6/33Response 6/33
Partial 6/33Partial 6/33 Total Total
14/33=42%14/33=42%
SymptomsSymptoms Improvement in 80% first Improvement in 80% first
2 weeks2 weeks Sustained at 5 months in Sustained at 5 months in
50%50%
Memory and AwarenessMemory and Awareness
Most patients report an Most patients report an improvement in cognitive, memory improvement in cognitive, memory and focusingand focusing
Brain characteristicsBrain characteristics This is an indicator of correlation This is an indicator of correlation
between toxins and brain functionbetween toxins and brain function
PhospholipidsPhospholipids
PlaquexPlaquex In the management of In the management of
cardiovascular diseases and cardiovascular diseases and detoxificationdetoxification
Our clinic in Miami started Our clinic in Miami started managing and detoxing patients managing and detoxing patients with IV phosphatidylcholinewith IV phosphatidylcholine
Neurological Diseases Neurological Diseases AdultsAdults
More than 85% of Alzheimer’s More than 85% of Alzheimer’s Disease patients will have an MRI Disease patients will have an MRI or CT scan showing white matter or CT scan showing white matter changes consistent with small changes consistent with small vessel ischemic disease.vessel ischemic disease.
A disease of brain toxicityA disease of brain toxicity Fourth leading cause of death in Fourth leading cause of death in
Puerto Rico. 6Puerto Rico. 6thth in the USA in the USA
Alzheimer’s DiseaseAlzheimer’s Disease
Gochi, Chlorella, Vitamin C and Gochi, Chlorella, Vitamin C and LactobacillusLactobacillus
Alkalinizing ProgramAlkalinizing Program Intravenous phosphatidylcholineIntravenous phosphatidylcholine 250-1500 mg IV Push or IV bag in 250-1500 mg IV Push or IV bag in
D5WD5W B12, GlutathioneB12, Glutathione WeeklyWeekly
Alzheimer’sAlzheimer’s
25 patients25 patients Marked improvement in 72% of the Marked improvement in 72% of the
patientspatients 2 had no response (8%)2 had no response (8%) 20% Moderate response20% Moderate response EDTA and PhosphatidylcholineEDTA and Phosphatidylcholine
DementiaDementia
10 patients 10 patients Marked improvement in most of Marked improvement in most of
their cognitive capacitiestheir cognitive capacities Improvement in socialization and Improvement in socialization and
orientation to placeorientation to place Last aspect to improve-Short term Last aspect to improve-Short term
memorymemory
Parkinson’s DiseaseParkinson’s Disease
5 patients5 patients Steady improvement in the first 2 Steady improvement in the first 2
months in 3/5months in 3/5 1 patient –No change1 patient –No change 1 patient-Dramatic improvement and 1 patient-Dramatic improvement and
reversal of all symptoms with PTC and reversal of all symptoms with PTC and pulsed electromagnetic frequencypulsed electromagnetic frequency
All patients now get PEMFAll patients now get PEMF
Chemotherapy Induced Chemotherapy Induced NeuropathyNeuropathy
Cisplatin, Carboplatin associatedCisplatin, Carboplatin associated Very painfulVery painful Feet and handsFeet and hands Does not respond well to Does not respond well to
analgesicsanalgesics
NeuropathyNeuropathy
Management with Management with phosphatidylcholinephosphatidylcholine
10 patients10 patients WeeklyWeekly Improvement in all patients in the Improvement in all patients in the
first two treatmentsfirst two treatments Complete Resolution of pain in 8 pts.Complete Resolution of pain in 8 pts. The earlier the betterThe earlier the better
ALSALS
8 patients8 patients One-EDTA, IVC, H2O2-no response. One-EDTA, IVC, H2O2-no response.
Died in less than a year Died in less than a year 2 more with PTC-No response2 more with PTC-No response 1 Pt. with 3x/day tx 15 txs. Week1 Pt. with 3x/day tx 15 txs. Week First week regained vocal cord and First week regained vocal cord and
swallowing movementswallowing movement
ALSALS
Stopped treatment after 3 months Stopped treatment after 3 months and deterioratedand deteriorated
One patient was stable for one One patient was stable for one year speaking and walking. Died year speaking and walking. Died from a fall from a fall
One patient improved and One patient improved and spasticity markedly improved with spasticity markedly improved with PTC and PEMFPTC and PEMF
ALSALS
Latest 2 patientsLatest 2 patients #1 in less than 2 weeks could #1 in less than 2 weeks could
understand previously unintelligible understand previously unintelligible speech. Swallowing better. speech. Swallowing better.
Improved pulmonary function studiesImproved pulmonary function studies #2 Could move extremities better in #2 Could move extremities better in
2 weeks2 weeks Both had daily treatmentBoth had daily treatment
Side EffectsSide Effects
Temporary (minutes) dizziness-2Temporary (minutes) dizziness-2 Extravasation and burning that Extravasation and burning that
would last days, weeks and would last days, weeks and sclerose veins temporarily 4%sclerose veins temporarily 4%
Months of sclerosing 3 patientsMonths of sclerosing 3 patients
AUTISMAUTISM
1:37 in Puerto Rico1:37 in Puerto Rico 1:50-75 in the USA1:50-75 in the USA No more figures presented in CDC No more figures presented in CDC
website since 2008website since 2008 Rapidly rising epidemicRapidly rising epidemic Maybe related to aluminum and Maybe related to aluminum and
mercury in vaccinesmercury in vaccines
AUTISMAUTISM
75 patients75 patients 7 Did not complete treatment7 Did not complete treatment Of the 68 remaining patientsOf the 68 remaining patients AnalysisAnalysis 75% trigered at 18 months of age 75% trigered at 18 months of age
related to vaccine booster dosesrelated to vaccine booster doses
AUTISMAUTISM
Eliminate sugar, complex Eliminate sugar, complex carbohydratescarbohydrates
Start nutritional alkalinizationStart nutritional alkalinization Intravenous phosphatidylcholineIntravenous phosphatidylcholine 250-1000 mg a week250-1000 mg a week Glutathione IV 400 mg a weekGlutathione IV 400 mg a week Methylcobalamin 1000 ugMethylcobalamin 1000 ug Folic acid 4 mgFolic acid 4 mg
AUTISMAUTISM
After 10-20 Weekly treatmentsAfter 10-20 Weekly treatments IV Phenylbutyrate 100-400 mg in 100 IV Phenylbutyrate 100-400 mg in 100
cc/d5wcc/d5w Continue if there was a steady Continue if there was a steady
improvementimprovement Side effects- Rash in 2 patients. Side effects- Rash in 2 patients.
Glutathione eliminated in them and it Glutathione eliminated in them and it resolved. They were both allergic to resolved. They were both allergic to eggseggs
RESULTSRESULTS
Frederick’s AtaxiaFrederick’s Ataxia
Hereditary diseaseHereditary disease Poor prognosisPoor prognosis Progressive Degenerative DiseaseProgressive Degenerative Disease 2 sisters 14, 16 years old2 sisters 14, 16 years old 5 treatments so far5 treatments so far Improvement in gait, fine motor Improvement in gait, fine motor
movements and energy levelsmovements and energy levels
CONCLUSIONSCONCLUSIONS
Phospholipid therapy reverses the Phospholipid therapy reverses the pathologic features of autism and pathologic features of autism and other neurological diseasesother neurological diseases
Phenylbutyrate seems to detoxify Phenylbutyrate seems to detoxify the brain and has a calming effect the brain and has a calming effect in all patientsin all patients
One to two years of therapy may One to two years of therapy may reverse all symptoms completelyreverse all symptoms completely
CONCLUSIONSCONCLUSIONS
Minimal side effects (allergic Minimal side effects (allergic reaction and itching in one patient)reaction and itching in one patient)